American Society of Hematology

Figure 1.

Study design. ACVBP, doxorubicin (75 mg/m2 at day 1), prednisone (60 mg/m2 day 1 to day 5), cyclophosphamide (1200 mg/m2 at day 1), vindesine (2 mg/m2 at days 1 and 5) and bleomycin (10 mg at days 1 and 5); BEAM, carmustine 300 mg/m2 at day −6; etoposide 200 mg/m2 from days −6 to −3; cytarabine 200 mg/m2 every 12 hours from days −6 to −3; melphalan 140 mg/m2 at day −2; C, cycle; CHOP, cyclophosphamide (750 mg/m2 at day 1), doxorubicin (50 mg/m2 at day 1), vincristine (1.4 mg/m2, maximum 2 mg, at day 1), and prednisone (40 mg/m2 day 1 to day 5); MTX, methotrexate.

Study design. ACVBP, doxorubicin (75 mg/m² at day 1), prednisone (60 mg/m² day 1 to day 5), cyclophosphamide (1200 mg/m² at day 1), vindesine (2 mg/m² at days 1 and 5) and bleomycin (10 mg at days 1 and 5); BEAM, carmustine 300 mg/m² at day −6; etoposide 200 mg/m² from days −6 to −3; cytarabine 200 mg/m² every 12 hours from days −6 to −3; melphalan 140 mg/m² at day −2; C, cycle; CHOP, cyclophosphamide (750 mg/m² at day 1), doxorubicin (50 mg/m² at day 1), vincristine (1.4 mg/m², maximum 2 mg, at day 1), and prednisone (40 mg/m² day 1 to day 5); MTX, methotrexate.

This Feature Is Available To Subscribers Only